MedPath

Effect Of a Goat Milk-Based Infant Formula On Gastrointestinal And Other Symptoms And Health-Related Quality Of Life.

Not Applicable
Not yet recruiting
Conditions
Infant Nutrition Disorders
Gastrointestinal Diseases
Interventions
Dietary Supplement: Goat milk-based infant formula
Dietary Supplement: Cow milk-based infant formula
Registration Number
NCT06108401
Lead Sponsor
Medical University of Warsaw
Brief Summary

In this trial, the investigators aim to assess impact of goat milk-based infant formula on the severity and frequency of gastrointestinal symptoms, as well as other associated symptoms, and the health-related quality of life in infants exhibiting symptoms possibly related to cow's milk, compared to a cow milk-based formula.

Detailed Description

Gastrointestinal symptoms are frequent in the first 6 months of life in otherwise healthy infants fed cow milk-based infant formulas (CMF). In management special infant formulas may be considered, although none is routinely recommended. Goat milk-based infant formulas (GMF) have shown promising effects on digestion and increased gastric emptying in several in vitro studies.

In this trial, a total of 158 participants at age 14 to 90 days, who exhibit gastrointestinal and/or other symptoms associated with CMF consumption, as assessed with the Cow's Milk-related Symptom Score (CoMiSS) between 6 and 10 will be randomly allocated to GMF or CMF for four weeks. The primary outcome will be the proportion of infants showing a reduction of at least 4 points in CoMiSS following the four-week intervention period.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
152
Inclusion Criteria
  • Healthy term infants with a gestational age between 37 and 42 weeks.
  • Infants who have received cow's milk infant formula for at least 7 consecutive days.
  • Exclusive formula feeding.
  • Cow's Milk-related Symptoms Score (CoMiSS) value at baseline between ≥6 and <10.
Exclusion Criteria
  • exclusive or partial breastfeeding (or feeding human milk)
  • introduced to solid food/supplementary feeding
  • any congenital or chronic condition
  • previous or present gastrointestinal illness or malformation that could interfere with study parameters
  • diagnosed cow's milk allergy
  • receiving medication with regard to functional gastrointestinal disorders (i.e., reflux medication)
  • sibling already participating in this study, and/or participating in another clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Goat milk formula-fed groupGoat milk-based infant formula79 participants
Cow milk formula-fed groupCow milk-based infant formula79 participants
Primary Outcome Measures
NameTimeMethod
Reduction of Cow's Milk-related Symptoms Score (CoMiSS) values after 4 weeks0 - 4 weeks

Proportion of infants with a reduction of 4 points or more in the CoMiSS value

Secondary Outcome Measures
NameTimeMethod
Adverse events0 - 4 weeks

Adverse events throughout the study period

Reduction of Cow's Milk-related Symptoms Score (CoMiSS) values after 2 weeks0 - 2 weeks

Proportion of infants with a reduction of 4 points or more in the CoMiSS value

Difference in Cow's Milk-related Symptoms Score (CoMiSS) values after 4 weeks0 - 4 weeks

Difference in the CoMiSS between infants fed with goat milk-based infant formula versus cow milk-based infant formula

The Pediatric Quality of Life Inventory (PedsQL) Infant Scales improvement after 2 weeks0 - 2 weeks

Proportion of infants with a PedsQL Infant Scale score of 80 or higher

Anthropometric parameters after 2 weeks0 - 2 weeks

Assessment of growth parameters, including length

Anthropometric parameters after 4 weeks0 - 4 weeks

Assessment of growth parameters, including length

Difference in Cow's Milk-related Symptoms Score (CoMiSS) values after 2 weeks0 - 2 weeks

Difference in the CoMiSS between infants fed with goat milk-based infant formula versus cow milk-based infant formula

Improvement in gastrointestinal symptoms measured by the Infant Gastrointestinal Symptom Questionnaire (IGSQ) after 4 weeks0 - 4 weeks

Change in the severity and frequency of gastrointestinal symptoms as measured by the IGSQ

The Pediatric Quality of Life Inventory (PedsQL) Infant Scales improvement after 4 weeks0 - 4 weeks

Proportion of infants with a PedsQL Infant Scale score of 80 or higher

Improvement in gastrointestinal symptoms measured by the Infant Gastrointestinal Symptom Questionnaire (IGSQ) after 2 weeks0 - 2 weeks

Change in the severity and frequency of gastrointestinal symptoms as measured by the IGSQ

Trial Locations

Locations (1)

Department of Paediatrics, The Medical University of Warsaw, Poland

🇵🇱

Warsaw, Poland

© Copyright 2025. All Rights Reserved by MedPath